Medicaid; excluding prescription drug services from certain provisions; directing certain program delivery model. Effective date.
SB 252 revises Oklahoma’s Medicaid managed care transformation framework under the Ensuring Access to Medicaid Act. The bill keeps the Oklahoma Health Care Authority (OHCA) in charge of issuing requests for proposals and entering capitated contracts for Medicaid delivery, but it changes how prescription drug services are handled. Under the bill, prescription drug services are excluded from the general managed care provisions and, once federal approval is obtained, must be covered through a fee-for-service model administered directly by OHCA rather than through contracted entities. The bill also directs OHCA to seek federal approval for the necessary waiver and financing arrangements before implementing the transformation.
The bill continues the state’s move toward public-private Medicaid partnerships for most services, including physical health, behavioral health, and dental coverage, and it preserves a separate Children’s Specialty Plan. It also requires statewide capitated contracts to be competitively bid and maintains preferences for provider-led and provider-owned entities, including scoring advantages and at least one statewide contract opportunity for those entities if they submit responsive bids. The bill further requires shared governance structures with local Oklahoma providers, uniform drug formularies, broad pharmacy access, data-sharing through the state health information exchange, and various reimbursement protections for providers.
SB 252 would affect several Medicaid-related statutes, including provisions governing capitated contracts, contracted entity responsibilities, and minimum reimbursement rates. It would require OHCA to amend existing contracts, establish direct reimbursement arrangements for pharmacy providers, and ensure network adequacy for pharmacy services under the new fee-for-service model. The bill also retains and updates reimbursement floors and payment rules for providers such as rural health clinics, community behavioral health clinics, psychologists, ambulance providers, anesthesia providers, and pharmacies, while preserving value-based payment options and primary care spending requirements.
The general sentiment reflected in the bill text is supportive of continued Medicaid transformation but with stronger guardrails, especially around prescription drugs, provider participation, and reimbursement. The measure appears designed to preserve managed care for most services while pulling pharmacy benefits back under direct state administration. No committee transcript or vote record was provided, so there is no recorded discussion or vote history to indicate broader legislative support or opposition.
The main points of contention suggested by the bill are the treatment of prescription drug services, the role of pharmacy benefit managers, and the balance between state control and managed care contracting. The bill explicitly prohibits contracting with a pharmacy benefits manager, allows a pharmacy benefits administrator located in Oklahoma, and requires direct payment to pharmacists and pharmacy providers. It also preserves preferential treatment for provider-led and provider-owned entities, which may be viewed as beneficial by local provider groups but potentially limiting by other bidders or managed care organizations.
SB 252 would amend Oklahoma Medicaid statutes to carve prescription drug services out of the managed care capitated-contract model and place them under direct OHCA fee-for-service coverage, subject to federal approval. It would also reinforce procurement, governance, reimbursement, and reporting requirements for contracted Medicaid entities, including provider ownership preferences, shared governance, minimum reimbursement floors, pharmacy access rules, and primary care spending targets. The bill would primarily affect OHCA, contracted Medicaid entities, providers, pharmacies, and Medicaid enrollees in the populations covered by the transformation.
The bill appears generally favorable toward Medicaid delivery reform, but with a clear policy preference for tighter state oversight and protections for providers and pharmacies. Its structure suggests support for managed care in most areas while rejecting private management of prescription drug benefits. Because no committee discussion or vote history was provided, there is no direct evidence of floor or committee sentiment beyond the bill’s text and sponsor action.
The most notable contention points are likely prescription drug administration, the prohibition on pharmacy benefit managers, and the preferential contracting rules for provider-led and provider-owned entities. Supporters of the bill would likely favor direct state control of drug benefits, stronger reimbursement protections, and local provider governance, while opponents may object to limiting managed care flexibility, restricting PBM involvement, and mandating contract preferences that could narrow competition. The bill also conditions implementation on federal approval and budget neutrality, which could be a practical point of dispute if those approvals are delayed or denied.